MedTrace Logo

Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome

NCT07399535 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2026-02-10

No results posted yet for this study

Summary

Polycystic Ovarian Syndrome (PCO) is a metabolic disorder that afflicts the women of childbearing age. An approximate of 5-10% women are the victim of this disorder. PCOS is a leading cause of infertility in females these days and is characterized by Hyperandrogenism, Chronic Anovulation, Impaired fertility, obesity, Hirsutism, Acne, Obesity, Metabolic disturbances (dyslipidemias, Hyperinsulinemia, insulin resistance, and type- 2 diabetes), and Endometrial Hyperplasia. This study will test a combination of herbal medications (Melats P) in women with PCOS to determine which works best to overcome infertility.

Conditions

  • Polycystic Ovarian Syndrome (PCOS)
  • Herbal Medicine
  • Infertility
  • Metabolic Disorder

Interventions

DRUG

Herbal Formulation

Herbal Formulation 500mg twice daily for 4 months in PCOS patients

DRUG

Metformin XR

Metformin XR 750mg twice daily for 4 months in PCOS patients

DRUG

Metformin 750 mg and herbal formulation 500 mg

Herbal formulation and Metformin twice daily for 4 months in PCOS patients

Sponsors & Collaborators

  • Jinnah Postgraduate Medical Centre

    lead OTHER_GOV

Principal Investigators

  • Saba Zubair, PhD scholar · University of Sindh Jamshoro

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-22
Primary Completion
2026-02-22
Completion
2026-03-01

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07399535 on ClinicalTrials.gov